Newsfiscal.ai
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
· Published
Article summary
Immutep Limited announced that it will present clinical trial data for its lead product candidate, eftilagimod alfa, at two international medical congresses in late 2026.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…


Comments —
Loading comments…